Isolated penile ulceration after Nivolumab therapy for non-small cell lung carcinoma.

Immune-related cutaneous events can develop after immunotherapy. To our knowledge, we present the first reported case of isolated focal penile inflammatory ulceration in a patient being treated with Nivolumab for stage IV non-small cell lung carcinoma. He presented with a painless penile ulceration two months after initiating therapy. He had near-complete resolution of his ulcer after two weeks of topical treatment. Histologic evaluation revealed a drug eruption. While cutaneous events are a well-known side effect of immunotherapy, this is the first report of an isolated penile lesion from such therapy.